PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation

OBJECTIVE—: BMS-986120 is a novel first-in-class oral PAR4 (protease-activated receptor 4) antagonist with potent and selective antiplatelet effects. We sought to determine for the first time, the effect of BMS-986120 on human ex vivo thrombus formation. APPROACH AND RESULTS—: Forty healthy voluntee...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, Simon J., Ismat, Fraz A., Wang, Zhaoqing, Cerra, Michael, Narayan, Hafid, Raftis, Jennifer, Gray, Timothy J., Connell, Shea, Garonzik, Samira, Ma, Xuewen, Yang, Jing, Newby, David E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Translational Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779320/
https://www.ncbi.nlm.nih.gov/pubmed/29269513
http://dx.doi.org/10.1161/ATVBAHA.117.310104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779320/
https://www.ncbi.nlm.nih.gov/pubmed/29269513
http://dx.doi.org/10.1161/ATVBAHA.117.310104

Ejemplares similares